PRAECIS PHARMACEUTICALS INCORPORATED To Announce Second Quarter 2004 Financial Results on Friday, July 30, 2004.WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : PRCS PRCS Palestine Red Crescent Society PRCS Permit Required Confined Space PRCS Primary Reaction Control System PRCS Senior Chief Parachute Rigger (Naval Rating) PRCS Pseudorandom Chip Stream PRCS Project Revision Control System ), today announced that it will report second quarter 2004 financial results on Friday, July 30, 2004, before the financial markets open. The release will be followed by a conference call with the investment community at 9:00 a.m., EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT , hosted by Malcolm L. Gefter, Ph.D., Chairman and Chief Executive Officer, and William K. Heiden, President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , along with other members of PRAECIS' senior management. The Company's conference call may be accessed live by visiting PRAECIS' website at http://www.praecis.com and clicking on Investors, then on Webcast Live. Interested parties also may listen to a replay of the call beginning Friday, July 30, at 12:00 Noon (EDT), until midnight Friday, August 6, by calling 888-203-1112, or 719-457-0820, and entering the passcode 200606. PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to address significant unmet medical needs. PRAECIS has received approval from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to market Plenaxis(R) (abarelix for injectable suspension) in the United States. PRAECIS employed its proprietary LEAP(TM) (Ligand Evolution to Active Pharmaceuticals) technology in the development of Plenaxis(R). PRAECIS also has an innovative product pipeline, including clinical programs in Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. and non-Hodgkin's lymphoma, as well as discovery programs in oncology, inflammation and anti-viral therapies. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion